Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): Focus on targeted therapies

Alessandro Cappetta, Sara Lonardi, Davide Pastorelli, Francesca Bergamo, Giuseppe Lombardi, Vittorina Zagonel

Research output: Contribution to journalArticlepeer-review


Despite recent improvements in surgical techniques and chemotherapy treatments, locally advanced/metastatic gastroesophageal junction (GEJ) and gastric cancer (GC) are still associated with poor clinical outcome. However, increased understanding of molecular mechanisms underlying carcinogenesis and its implementation in the treatment of breast, colon, lung, and other cancers in recent years have spurred focus on the development and incorporation of targeted agents in current therapeutic options for this difficult-to-treat disease. Such agents have the ability to target a variety of cancer relevant targets, including epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) and its receptor. In this review, we describe the current status of targeted therapies in the treatment of advanced GC and GEJ cancer, focusing on pre-clinical and clinical data available on monoclonal antibodies and tyrosine kinase inhibitors acting in these pathways, including completed and ongoing phase III studies.

Original languageEnglish
Pages (from-to)38-48
Number of pages11
JournalCritical Reviews in Oncology/Hematology
Issue number1
Publication statusPublished - Jan 2012


  • Gastric cancer
  • Gastro-oesophageal junction cancer
  • Monoclonal antibody
  • Targeted therapy
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology


Dive into the research topics of 'Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): Focus on targeted therapies'. Together they form a unique fingerprint.

Cite this